Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析

◆英語タイトル:Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15440
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Glenmark Pharmaceuticals Ltd (GLENMARK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company’s formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies. The company markets its products in North America, South America, Asia-Pacific and Africa.

Glenmark Pharmaceuticals Ltd Key Recent Developments

Mar 06,2019 Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15,2019 Glenmark Pharmaceuticals to establish new company in US
Feb 14,2019 Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Dec 19,2018 Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Glenmark Pharmaceuticals Ltd – Key Facts
Glenmark Pharmaceuticals Ltd – Key Employees
Glenmark Pharmaceuticals Ltd – Key Employee Biographies
Glenmark Pharmaceuticals Ltd – Major Products and Services
Glenmark Pharmaceuticals Ltd – History
Glenmark Pharmaceuticals Ltd – Company Statement
Glenmark Pharmaceuticals Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Glenmark Pharmaceuticals Ltd – Business Description
Product Category: Other Operating Revenue
Performance
Product Category: Sale of Products
Performance
Product Category: Sale of Services
Performance
Geographical Segment: Europe
Performance
Geographical Segment: India
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World (ROW)
Performance
Geographical Segment: USA
Performance
R&D Overview
Glenmark Pharmaceuticals Ltd – Corporate Strategy
Glenmark Pharmaceuticals Ltd – SWOT Analysis
SWOT Analysis – Overview
Glenmark Pharmaceuticals Ltd – Strengths
Glenmark Pharmaceuticals Ltd – Weaknesses
Glenmark Pharmaceuticals Ltd – Opportunities
Glenmark Pharmaceuticals Ltd – Threats
Glenmark Pharmaceuticals Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 06, 2019: Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15, 2019: Glenmark Pharmaceuticals to establish new company in US
Feb 14, 2019: Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Dec 19, 2018: Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States
Nov 13, 2018: Glenmark’s consolidated revenue rises 14.39% to Rs. 25,813.32 Mn. in Q2 FY 2018–19
Nov 07, 2018: Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
Oct 30, 2018: Glenmark Pharmaceuticals celebrates the inauguration of its U.S. manufacturing site in Monroe, North Carolina
Oct 18, 2018: Data on Glenmark Pharmaceuticals” GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Glenmark Pharmaceuticals Ltd, Key Facts
Glenmark Pharmaceuticals Ltd, Key Employees
Glenmark Pharmaceuticals Ltd, Key Employee Biographies
Glenmark Pharmaceuticals Ltd, Major Products and Services
Glenmark Pharmaceuticals Ltd, History
Glenmark Pharmaceuticals Ltd, Other Locations
Glenmark Pharmaceuticals Ltd, Subsidiaries
Glenmark Pharmaceuticals Ltd, Key Competitors
Glenmark Pharmaceuticals Ltd, Ratios based on current share price
Glenmark Pharmaceuticals Ltd, Annual Ratios
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...1)
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...2)
Glenmark Pharmaceuticals Ltd, Interim Ratios
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Glenmark Pharmaceuticals Ltd, Performance Chart (2014 - 2018)
Glenmark Pharmaceuticals Ltd, Ratio Charts
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BE Semiconductor Industries N.V. (BESI):企業の財務・戦略的SWOT分析
    BE Semiconductor Industries N.V. (BESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Gilead Sciences Inc (GILD)-医療機器分野:企業M&A・提携分析
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) in …
  • Inform Genomics Inc-医療機器分野:企業M&A・提携分析
    Summary Inform Genomics Inc (Inform Genomics) manufactures and markets genomic-based personalized medicine products for cancer and supportive care. The company’s onpart is a medicinal product, which is used for the treatment of decisions in patients, who receive chemotherapy for colorectal, breast, …
  • Bioverativ Inc (BIVV):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technolog …
  • Canadian Solar Inc (CSIQ):企業の財務・戦略的SWOT分析
    Canadian Solar Inc (CSIQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Hyundai Heavy Industries Co., Ltd.:企業の戦略・SWOT・財務分析
    Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • The Eighteenth Bank, Ltd.:企業の戦略・SWOT・財務情報
    The Eighteenth Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Eighteenth Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Visa Inc:企業の戦略・SWOT・財務情報
    Visa Inc - Strategy, SWOT and Corporate Finance Report Summary Visa Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Puma SE (PUM):企業の財務・戦略的SWOT分析
    Puma SE (PUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Gujarat Industries Power Co Ltd (GIPCL):企業の財務・戦略的SWOT分析
    Gujarat Industries Power Co Ltd (GIPCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Eaton Corporation Plc (ETN):企業の財務・戦略的SWOT分析
    Eaton Corporation Plc (ETN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Brown Advisory Inc:企業の戦略・SWOT・財務分析
    Brown Advisory Inc - Strategy, SWOT and Corporate Finance Report Summary Brown Advisory Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Chicago Bridge & Iron Company NV (CBI)-エネルギー分野:企業M&A・提携分析
    Summary Chicago Bridge & Iron Company N.V. (CB&I) is a provider of technology and infrastructure solutions. Its services include conceptual design, technology, engineering, procurement, modularization, construction, fabrication, commissioning, maintenance, program management and environmental servic …
  • Murree Brewery Co. Ltd.:企業の戦略・SWOT・財務分析
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Foraco International SA (FAR):企業の財務・戦略的SWOT分析
    Summary Foraco International SA (Foraco) is a provider of drilling solutions for mining, energy, water and infrastructure projects. The company's drilling solutions include hydrogeological drilling, deep directional drilling, metallurgical sampling and large diameter drilling. It provides geological …
  • Gentag Inc:医療機器:M&Aディール及び事業提携情報
    Summary Gentag Inc (Gentag) is a medical device company that patent and develops wireless sensor technology products. The company provides wireless products to diagnostics and personal health. It offers wireless sensor network services. Gentag’s products comprise medication and packaging sensor, dia …
  • Global Petroleum Ltd (GBP):企業の財務・戦略的SWOT分析
    Summary Global Petroleum Ltd (Global Petroleum) is an oil and gas company that offers oil and gas exploration and development services. It operates through a portfolio of oil and gas projects in offshore Namibia and others. Its Namibian Project is into petroleum and gas exploration and Juan de Nova …
  • Aegis Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Aegis Therapeutics LLC (Aegis Therapeutics) is a biotechnology company that research and develops drug delivery and drug formulation technologies. The company commercializes new drug delivery and protein stabilization technologies through product specific licenses to pharmaceutical and bioph …
  • Asplundh Tree Expert LLC:企業の戦略的SWOT分析
    Asplundh Tree Expert LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Aprecia Pharmaceuticals Company:製薬・医療:M&Aディール及び事業提携情報
    Summary Aprecia Pharmaceuticals Company (Aprecia) is a drug delivery technology platform company that develops pharmaceutical drug products. The company offers Zipdose technology, a delivery platform that serves as the foundation of orodispersible formulations of prescribed high-dose medications. It …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆